Nurix Therapeutics Inc
(NAS:NRIX)
$
22.11
0.88 (4.15%)
Market Cap: 1.57 Bil
Enterprise Value: 1.15 Bil
PE Ratio: 0
PB Ratio: 3.94
GF Score: 48/100 Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 18, 2022 / 03:00PM GMT
Release Date Price:
$10.01
(-4.21%)
Greg Renza
RBC Capital Markets - Senior Biotechnology Analyst
Welcome back to the 2022 RBC Global Healthcare Conference. My name is Greg Renza, one of the biotechnology equity research analysts here at RBC, and we're pleased to be joined today by Nurix therapeutics. And joining us from the Company is the CEO, Arthur Sands and the EVP of Finance business and strategy, Jason Kantor.
Gentlemen, thanks. Thanks for being here.
Arthur Sands
Nurix Therapeutics - President & CEO
Thanks for having us, Greg.
Questions & Answers
Greg Renza
RBC Capital Markets - Senior Biotechnology Analyst
It's good to see you again and to be in person. And maybe for those who aren't as familiar with the Nurix story. Maybe you can provide us an overview, Arthur, of the company, of the portfolio.
Arthur Sands
Nurix Therapeutics - President & CEO
Sure. So, we create small molecule drugs for drug discovery company and a particular new area of medicine, which is called
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot